RecruitingPhase 1NCT06249438

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Studying Systemic lupus erythematosus

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
RenJi Hospital
Principal Investigator
Nan Shen, MD & PhD
Department of Rheumatology, RenJi Hospital, School of Medicine, Shanghai JiaoTong University
Intervention
CD20/BCMA-directed CAR-T cells(biological)
Enrollment
30 enrolled
Eligibility
18-70 years · All sexes
Timeline
20242040

Study locations (1)

Collaborators

AbelZeta Pharma Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06249438 on ClinicalTrials.gov

Other trials for Systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

See all trials for Systemic lupus erythematosus

← Back to all trials